Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$168.59 USD

168.59
4,377,458

+2.03 (1.22%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $168.50 -0.09 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Here's What's Has Happened in the HCV Space Lately

by Zacks Equity Research

A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.

    AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why

    by Zacks Equity Research

    AbbVie's (ABBV) shares have gained an impressive 16.7% in the past month supported by a series of positive news for the company in the past few weeks.

      Arpita Dutt headshot

      Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation

      by Arpita Dutt

      Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.

        Arpita Dutt headshot

        Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?

        by Arpita Dutt

        With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.

          Merck Drops Two HCV Combination Programs Amid Competition

          by Zacks Equity Research

          Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.

            Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China

            by Zacks Equity Research

            Gilead Sciences' (GILD) blockbuster hepatitis C virus (HCV) infection drug, Sovaldi is now approved in China also.

              Arpita Dutt headshot

              Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues

              by Arpita Dutt

              Key highlights this week include Amgen's (AMGN) update regarding Hurricane Maria and safety issues concerning Intercept's Ocaliva.

                Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer

                by Zacks Equity Research

                AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.

                  Gilead's (GILD) Epclusa Receives Label Expansion in Canada

                  by Zacks Equity Research

                  Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

                    by Arpita Dutt

                    Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.

                      Roche (RHHBY) Announces Positive Data on Leukemia Drug

                      by Zacks Equity Research

                      Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.

                        J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU

                        by Zacks Equity Research

                        J&J's (JNJ) pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis received a positive opinion from the CHMP in the EU.

                          Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx

                          by Zacks Equity Research

                          Novartis' (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.

                            Arpita Dutt headshot

                            Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data

                            by Arpita Dutt

                            Key highlights include Alexion's (ALXN) restructuring plans and promising data from Kura Oncology on its lead pipeline candidate.

                              AbbVie's RA Candidate Meets Primary Endpoint in Phase III

                              by Zacks Equity Research

                              AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.

                                AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb

                                by Zacks Equity Research

                                AbbVie's (ABBV) eczema candidate upadacitinib meets primary endpoints in a phase IIb trial for treating atopic dermatitis. The company aims to advance the candidate to the next study level in 2018.

                                  Regeneron's Cemiplimab Gains Breakthrough Therapy Status

                                  by Zacks Equity Research

                                  Regeneron (REGN) and partner Sanofi's skin cancer candidate cemiplimab gets the FDA-granted Breakthrough Therapy status. The companies also anticipate submitting a BLA in the first-quarter 2018.

                                    AbbVie Inc. (ABBV) in Focus: Stock Moves 6.1% Higher

                                    by Zacks Equity Research

                                    AbbVie (ABBV) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.

                                      AbbVie Submits NDA for Endometriosis Candidate to the FDA

                                      by Zacks Equity Research

                                      AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.

                                        Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead

                                        by Zacks Equity Research

                                        The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.

                                          The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

                                          by Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

                                            Gilead to Fly High with Kite Pharma Acquisition for $11.9B

                                            by Zacks Equity Research

                                            Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.

                                              The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance

                                              by Zacks Equity Research

                                              The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance

                                                Roche's Gazyva Gets Priority Review for Follicular Lymphoma

                                                by Zacks Equity Research

                                                Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.

                                                  Biogen's Humira Biosimilar Imraldi Gets Approval in EU

                                                  by Zacks Equity Research

                                                  Biogen Inc.'s (BIIB) biosimilar version of AbbVie's top-selling blockbuster drug, Humira has been approved by the European Commission.